Yatsen Pivoted Strategy to Clinical Beauty Research
Beauty operators must track rising R&D investment as consumers move from marketing hype to ingredient-led product scrutiny.
Updated on Sept. 25, 2026 in Business Strategy
Live Poll
Do you prefer beauty products backed by clinical research over those driven by social media trends?
In 2025, Yatsen Global completed a multi-year pivot from fast-beauty product launches to a model centered on clinical research and development. The shift prioritizes long-term brand loyalty through functional ingredients.
Why it matters
The change responds to a broader consumer migration away from marketing-heavy trends toward products with verified, ingredient-focused skin benefits. Companies failing to provide clinical proof may struggle to retain market share among educated buyers.
Yatsen invested RMB 137 million in 2025, representing 3.2% of its total revenue. The firm now supports its portfolio with 240 patents and a 153-person research team across three international centers.
The players
Yatsen Global
A beauty company that owns brands including Dr Wu, Galénic, and Eve Lom and focuses on international market research.
IFSCC Congress
An international organization for cosmetic chemists that serves as a venue for presenting peer-reviewed beauty innovation research.
The details
Yatsen operationalized this shift by integrating direct consumer performance complaints into its chemists' daily formulation workflows. The firm uses specialized technology, such as essence-powder development, to engineer unique product variations for regional markets like Japan. It also validates its technical approach by presenting findings at specialized industry events like the IFSCC Congress.
Timeline
2020: The company initiated its current R&D investment period.
2025: Annual R&D expenditure reached RMB 137 million.
Market Landscape
This strategy follows the documented industry-wide shift of major beauty firms prioritizing scientific verification over rapid, trend-based consumer marketing. By moving toward clinical-grade R&D, Yatsen aligns with competitors who are increasingly using patent-backed technology to build long-term brand loyalty.
Operators in the consumer goods space should audit their product feedback loops to see if technical formulation improvements can directly address common customer complaints. Prioritize R&D spending that builds defensible intellectual property, as consumers increasingly scrutinize the functional efficacy of beauty products.
The takeaway
The move to clinical beauty highlights the necessity of evolving product lines to meet higher consumer standards for technical proof. Evaluate whether your brand's innovation roadmap provides the granular ingredient transparency that today's market demands.
Further reading
For more on evolving corporate structures, visit the Business Strategy section.
Source note: This article includes information reported by Inside Retail Asia.
Live Poll
Do you prefer beauty products backed by clinical research over those driven by social media trends?
